In Marian's honor, her husband Dr. Herbert Kleber, their children and stepchildren, Elizabeth Kleber, Marc and Judith Kleber, Pamela Kleber-Shad and Rees Shad, Eric and Reva Fischman, Sharon Fischman and Michael Lazar, and Amanda and Matthew Henshon, in collaboration with many colleagues, both in CPDD and all across the country have established the CPDD Marian W. Fischman Memorial Lectureship. It is fitting that the first lectureship established by CPDD be in remembrance of Marian, who was not only a wise, loving, and brave human being, but an outstanding scientist and mentor as well.

Previous Recipients of the Marian W. Fischman Memorial Award

2002	Chris-Ellyn Johanson
2003	Maxine Stitzer
2004	Nancy K. Mello
2005	Mary Jeanne Kreek
2006	Línda Dykstra
2007	Dorothy K. Hatsukamí
2008	Edythe D. London
2009	Harriet de Wit
2010	Línda B. Cottler
2011	Bertha K. Madras
2012	Marilyn E. Carroll
2013	Kathryn Cunningham



13th Annual Marían W. Físchman Memorial Lectureshíp

ಹೆಕ್ಕುಕ್ಕಿಕ್ಕಿಕ್ಕಿಕ್

Award Presented to Amy H. Newman by Michael Nader

Monday, June 16, 2014 at 4:15 P.M Caríbe Hílton Ballroom B San Juan, Puerto Ríco

MARIAN W. FISCHMAN LECTURESHIP 2014 AWARDEE



Amy H. Newman, Ph.D.
Director, Medication Development Program
National Institute on Drug Abuse
Baltimore, MD

Amy Hauck Newman, Ph.D., is the Deputy Scientific Director and Chief of the Molecular Targets and Medications Discovery Branch and the Medicinal Chemistry Section, of the National Institute on Drug Abuse-Intramural Research Program (NIDA-IRP), in Baltimore. She also serves as the Director of the NIDA-IRP Medications Development Program. She obtained her Ph.D. degree in Medicinal Chemistry from the Medical College of Virginia, Virginia Commonwealth University and did post-doctoral research at the National Institute of Diabetes, Digestive and Kidney Diseases, NIH. She began her independent research career at the Walter Reed Army Institute of Research and joined the NIDA-IRP in 1991. She was appointed to the NIH tenure track in 1994 and was awarded tenure in 1999 when she also became Chief of the Medicinal Chemistry Section. Her research effort is focused on the design, synthesis and pharmacological evaluation of novel small molecules as tools to study mechanisms underlying psychostimulant addiction targeting the dopamine and serotonin transport systems and the dopamine D2 family (D2/D3) of receptors. She has published ~220 papers and invited reviews in peer-reviewed journals and holds 10 patents or patent applications. She serves on numerous editorial boards, a broad range of NIH, NIDA and academic committees, is an elected member of the American College of Neuropsychopharmacology, and has mentored >25 postdoctoral and post-baccalaureate fellows.



MARIAN WEINBAUM FISCHMAN October 13, 1939 – October 23, 2001

Marian Rita Weinbaum was born in Queens, graduated from Barnard College, earned a M.S. in Psychology from Columbia University, and then a doctorate in Psychology from the University of Chicago in 1972. She then joined the Chicago faculty until 1984 when she moved to Johns Hopkins as Associate Professor in the Division of Behavioral Biology. In 1990, she was promoted to Professor at Hopkins. In 1992, she became Professor with Tenure at Columbia University where she co-founded the Division on Substance Abuse in the Department of Psychiatry with her husband, Herbert D. Kleber, M.D., and founded as well the Substance Use Research Center at the New York State Psychiatric Institute. Although Marian made important contributions to the study of treatment of heroin and marijuana abuse, her primary work was in the area of stimulants. Her Ph.D. thesis on methamphetamine, under the guidance of Bob Schuster and Lou Seiden, opened up the study of long-term methamphetamine toxicity. Her contributions to cocaine research fall in two principal areas. The initial one was to develop innovative techniques for the study of cocaine in humans. Hers was the first laboratory in the United States, in the mid-1970's at the University of Chicago, to be given permission to administer cocaine to human subjects and the first funded by NIDA for that work. She was the first investigator since Sigmund Freud to conduct controlled studies documenting the physiological and behavioral effects of cocaine in humans and the correlation between them. Her second major contribution was the development of unique protocols for assessing the efficacy of potential medications to treat cocaine abuse using a human laboratory model. In 1987, she received the first NIDA Merit Award, which provided 10 years of funding for these endeavors. Her protocol provided a bridge between pre-clinical studies with non-humans and large-scale out-patient trials, contributing an improved basis for developing substance abuse treatment interventions. Dr. Fischman was a mentor to a generation of young investigators and took a special pleasure in mentoring young women scientists about how to combine career and family. She was an inspiration to many women in the sciences and a passionate advocate both for research and how to carry it out ethically. Her three children and four grandchildren were a critical part of her life and a source of great pleasure. Her enthusiasm, joy for life, and her smile that lit up any room she entered were noted by all who knew her.